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Antiprion prophylaxis by gene transfer of a soluble prion
antagonist
Abstract
Prion diseases are untreatable neurodegenerative disorders characterized by accumulation of PrP(Sc), an
aggregated isoform of the normal prion protein PrP(C). Here, we delivered the soluble prion antagonist
PrP-Fc(2) to the brains of mice by lentiviral gene transfer. Although naïve mice developed scrapie at
175 +/- 5 days postintracerebral prion inoculation (dpi), gene transfer before inoculation delayed disease
onset by 72 +/- 4 days. At 170 days postintracerebral prion inoculation, PrP(Sc) accumulation and prion
infectivity in PrPFc-treated brains were reduced by 3.6 and 4.2 logs, respectively. When PrP-Fc(2) was
delivered 30 days after prion inoculation, survival of the treated animals was extended by 25 days. We
then used tissue-specific recombination to express PrP-Fc(2) in the entire central nervous system, in
only astrocytes, or in only oligodendrocytes. Oligodendrocyte-restricted PrP-Fc(2) expression impaired
PrP(Sc) deposition and delayed disease even though oligodendrocytes are completely resistant to prion
infection, suggesting that PrP-Fc(2) affords protection via noncell autonomous mechanisms. These
results suggest that somatic gene transfer of prion antagonists may be effective for postexposure
prophylaxis of prion diseases.
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Prion diseases are untreatable neurodegenerative dis-
orders characterized by accumulation of PrPSc, an
aggregated isoform of the normal prion protein PrPC.
Here, we delivered the soluble prion antagonist PrP-
Fc2 to the brains of mice by lentiviral gene transfer.
Although naı¨ve mice developed scrapie at 175  5
days postintracerebral prion inoculation (dpi), gene
transfer before inoculation delayed disease onset by
72  4 days. At 170 days postintracerebral prion in-
oculation, PrPSc accumulation and prion infectivity in
PrPFc-treated brains were reduced by 3.6 and 4.2 logs,
respectively. When PrP-Fc2 was delivered 30 days af-
ter prion inoculation, survival of the treated animals
was extended by 25 days. We then used tissue-specific
recombination to express PrP-Fc2 in the entire central
nervous system, in only astrocytes, or in only oligo-
dendrocytes. Oligodendrocyte-restricted PrP-Fc2 ex-
pression impaired PrPSc deposition and delayed dis-
ease even though oligodendrocytes are completely
resistant to prion infection, suggesting that PrP-Fc2
affords protection via noncell autonomous mecha-
nisms. These results suggest that somatic gene trans-
fer of prion antagonists may be effective for postex-
posure prophylaxis of prion diseases. (Am J Pathol
2008, 172:1287–1296; DOI: 10.2353/ajpath.2008.070836)
To date, no efficacious treatments for prion diseases are
available in clinical settings.1,2 Anti-PrP antibodies can
delay scrapie after peripheral challenge of prions.3,4
However, this strategy does not target PrPSc replication in
the brain, and intracerebral delivery of anti-PrPC antibod-
ies may be neurotoxic.5 Active immunization strategies
are meeting with little success most likely because en-
dogenous PrPC induces robust immune tolerance.6,7
Transgenic expression of a soluble dimeric PrP, termed
PrP-Fc2, affects prion propagation and scrapie patho-
genesis by interfering with the buildup of PrPSc.8 The high
solubility and stability of PrP-Fc2 prompted us to explore
its therapeutic potential. We therefore used lentiviral vec-
tors9 to investigate in a scrapie mouse model whether
sustained intracerebral expression of PrP-Fc2 inhibits
prion replication.
Materials and Methods
Mice
Mouse lines tg550Stop, carrying a loxP-flanked transcrip-
tion-termination cassette upstream of the open reading
frame of PrPFc, and tg588CMV, in which the transcription-
termination cassette was eliminated, were described pre-
viously.8 Mice carrying the Cre recombinase under the
transcriptional control of the Nestin, glial fibrillary acidic
protein (GFAP), or proteolipid protein (PLP) regulatory ele-
ments have been described elsewhere.10–12 tg550Stop 
PLP/Cre-ERT2, tg550Stop (but Cre-negative), and PLP/Cre-
ERT2 (but tg550Stop-negative) littermates were treated with
tamoxifen dissolved in a sunflower oil/ethanol (10:1)
mixture at 10 mg/ml. Twice 1 mg of tamoxifen per day
for 5 consecutive days was injected intraperitoneally,
as described.12
Vector Production and Injection
PrPFc cDNA was cloned into the lentiviral vector
pRRL.sin.cPPT.hCMV.GFP.Wpre9 in place of GFP. Vec-
tors stocks were generated as described9 by co-trans-
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fection of 293T with pCMV-R8.91,13 pMD.G,13 and
pRRL.sin.cPPT.hCMV.PrPFc vectors. 293T-conditioned
media were filtered and ultracentrifuged to concentrate
the vector.9 Particle content was measured by HIV-1 p24
antigen immunocapture.9 HIV-1 p24 concentration was
between 500 to 600 g/ml (corresponding to 100,000
infectious units per ng of p24). C57BL/6 mice were slowly
injected with 5 l of the lentiviral preparations or phos-
phate-buffered saline (PBS) stereotaxically into the hip-
pocampus or 30 l intracerebrally into the right telence-
phalic hemisphere. Integration of the transgene was
detected by polymerase chain reaction (PCR) with stan-
dard conditions using primers amplifying the PrP and Fc
regions (Table 1).
Western Blot Analysis and NaPTA Precipitation
Sodium phosphotungstate precipitation and quantitative
Western blot were performed as described.8 Brain and
spleen samples were digested for 30 minutes at 37°C with
50 g/ml and 20 g/ml of proteinase K, respectively. Anti-
body incubations were done in 1% Top-Block (Sigma-Al-
drich Chemia GmbH, Buchs, Switzerland) in Tris-buffered
saline Tween 20 with ICSM183 or POM114 for PrP and
PrP-Fc2 for 1 hour at room temperature or overnight at 4°C.
The samples were analyzed with a VersaDoc digital imager
(model 5000; Bio-Rad, Hercules, CA).
Bone Marrow (BM) Chimeric Mice
BM cells (5  106) were isolated from tibiae and femurs,
and injected into tail veins of 8- to 10-week-old recipients
conditioned by whole-body irradiation (1100 rad). Sev-
eral paradigms were generated: wt BM was injected into
wt or tg588-irradiated mice, and tg588 BM was injected
into wt or tg588-irradiated mice. The tg588CMV line (for
brevity tg588) was used in the BM reconstitution experi-
ments because of the sixfold higher expression of PrP-
Fc2 in spleen in tg588 compared to tg550.
8 Eight weeks
after grafting, reconstitution was assessed by enzyme-
lined immunosorbent assay (ELISA) analysis of periph-
eral blood taken from the retro-orbital plexus of ether-
anesthetized mice.
ELISA Analysis
ELISA to detect PrP-Fc2 was performed as described.
3,4
Briefly, plates (Maxisorp; Nunc, Roskilde, Denmark) were
coated with monoclonal anti-PrP antibody ICSM 18,
washed with PBS containing 0.1% (v/v) Tween 20 (PBST),
and blocked with 5% bovine serum albumin (BSA). After
washing, plates were incubated with 30 l of twofold
serially diluted serum (1:20 prediluted) in PBST contain-
ing 1% BSA and then probed with horseradish peroxi-
dase-conjugated goat anti-human IgG-Fc horseradish
peroxidase (1:1000 dilution; Rockland Immunochemi-
cals, Gilbertsville, PA). Plates were developed with 2,2-
azino-diethyl-benzothiazolinsulfonate, and optical den-
sity was measured at 405 nm. Titer was defined as the
highest dilution showing an OD more than two times the
technical background, which was calculated as the av-
erage of uncoated wells and wells incubated omitting
serum. For detection of anti-human Fc and anti-GFP an-
tibodies in serum of lentivirus-treated mice, the plates
were coated with purified human Fc and GFP-His,15 re-
spectively. The antibodies from the serum were detected
in the plates by using rabbit anti-mouse IgG  A  M
(H  L)-horseradish peroxidase conjugate (Zymed/In-
vitrogen AG, Basel, Switzerland).
Histopathology
Brains were fixed in 4% paraformaldehyde, paraffin-em-
bedded, and cut into 2-m sections. Sections were
stained with hematoxylin and eosin (H&E) and with anti-
GFAP.16 Histoblots were performed according to pub-
lished protocols.17 For immunohistochemistry, cryosec-
tions were fixed 5 minutes in paraformaldehyde, 2
Table 1. Sequences of PCR Primers and PrPFc Open Reading Frame
Forward primer recognizing PrP-moiety of PrPFc
5-AACGACTGGGAGGACCGCTA-3
Reverse primer recognizing Fc-moiety of PrPFc
5-CCTTGCCATTCAGCCAGTCC-3
Open reading frame of PrPFc
5-ATGGCGAACCTTGGCTACTGGCTGCTGGCCCTCTTTGTGACTATGTGGACTGATGTCGGCCTCTGCAAAAAGCGGCCAAAGCCTGGAGGGTGGAA-
CACCGGTGGAAGCCGGTATCCCGGGCAGGGAAGCCCTGGAGGCAACCGTTACCCACCTCAGGGTGGCACCTGGGGGCAGCCCCACGGTGGTGGC-
TGGGGACAACCCCATGGGGGCAGCTGGGGACAACCTCATGGTGGTAGTTGGGGTCAGCCCCATGGCGGTGGATGGGGCCAAGGAGGGGGTACC-
CATAATCAGTGGAACAAGCCCAGCAAACCAAAAACCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGCTGGGGCAGTAGTGGGGGGCCTTGGTGG-
CTACATGCTGGGGAGCGCCATGAGCAGGCCCATGATCCATTTTGGCAACGACTGGGAGGACCGCTACTACCGTGAAAACATGTACCGCTACCCTA-
ACCAAGTGTACTACAGGCCAGTGGATCAGTACAGCAACCAGAACAACTTCGTGCACGACTGCGTCAATATCACCATCAAGCAGCACACGGTCACC-
ACCACCACCAAGGGGGAGAACTTCACCGAGACCGATGTGAAGATGATGGAGCGCGTGGTGGAGCAGATGTGCGTCACCCAGTACCAGAAGGAGT-
CCCAGGCCTATTACGACGGGAGAAGATCCGGGGGCCTCGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAGGGGGCACCG-
TCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA-
GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCG-
TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCTCCA-
TCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGT-
CAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC-
GCCTCCCGTGTTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCA-
TGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA-3’
Target sequences of the primers are underlined.
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minutes in 50% acetone, 2 minutes in 100% acetone, 2
minutes in 50% acetone, PBS-washed, and blocked for
30 minutes in 5% donkey serum. Rabbit anti-human Fc
(Jackson ImmunoResearch Laboratories, West Grove,
PA) diluted 1:1000 in 0.5% BSA was used as primary
antibody and biotinylated donkey anti-rabbit (Jackson
ImmunoResearch Laboratories) was used as a second-
ary antibody diluted 1:100 in 0.5% BSA. In our experi-
ence, histoimmunochemical detection of PrP-Fc2 in tis-
sue sections proved difficult because PrP-Fc2 is a
molecule secreted from cells.
Prion Inoculations
Mice were inoculated intracerebrally or intraperitoneally
with 3  102 or 103 LD50 infectious units of Rocky Moun-
tain Laboratory strain (RML, passage 5) scrapie prions
prepared as described.8 Mice were sacrificed on the day
of onset of terminal clinical signs of scrapie. Significance
P values were derived by comparing mean survival (Stu-
dent’s t-test; two-tailed distribution, two-sample unequal
variance). Survival data were plot by using GraphPad
Prism 4.
Infectivity Bioassays with tga20 Mice
Assays were performed on 1% homogenates of brain or
of spleen tissues as described.18 Tissues were homoge-
nized in 0.32 mol/L sucrose with a homogenizer and
diluted 1:10 in 5% BSA in PBS. Supernatants (30 l) were
inoculated intracerebrally into groups of three to four
tga20 mice.19 Infectivity titers were calculated as
described.20
Scrapie Cell Assay in Endpoint Format (SCEPA)
For SCEPA, highly RML prion-susceptible neuroblastoma
cells (subclone N2aPK121) were exposed to prion sam-
ples for 3 days in 96-well plates, and split three times 1:3
every 2 days, and three times 1:10 every 3 days. After
reaching confluence, 25,000 cells from each well were
filtered onto the membrane of white Immobilon P plate
(Millipore, Billerica, MA) treated with PK, denatured, and
individual infected (PrPSc-positive) cells were detected
by ELISA using antibody POM-1 to PrP. After reaching
confluence, 25,000 cells from each well were processed
as above. Wells were counted positive if the spot number
was clearly exceeding background. From the proportion
of negative to total wells the number of infectious tissue
culture (TCI) units per aliquot was calculated by the
Poisson equation as described previously.21 The potency
of the SCEPA is based on the finding that the proportion
of infected cells, and with it the signal-to-background
ratio, increases on average 25% per day during cultur-
ing. The sensitivity of the assay can be further enhanced
by increasing the number of replicate samples and the
number of 1:10 splits.
Preparation of Cerebellar Granule Cells,
Oligodendrocytes, and Astrocytes
Cerebellar granule neurons were prepared from 7- to
8-day-old mice as previously described.22 Contamination
with glial cells was 5%. Mixed glial cell cultures con-
taining oligodendrocytes and astrocytes were produced
from 1-day-old neonatal mice as described.23,24 Cultures
were prepared with high-glucose Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine se-
rum and replenished on day 4 and every 3 to 4 days
thereafter for 10 days, with Dulbecco’s modified Eagle
medium plus 10% heat-inactivated horse serum. Oligo-
dendrocytes were purified from mixed glial cultures by
differential detachment and negative selection of micro-
glia by adherence to hydrophobic plastic. Purified oligo-
dendrocytes were then plated onto glass or plastic cul-
ture chambers coated, respectively, with 100 g/ml or 10
g/ml poly-L-lysine, whereas astrocytes were kept in the
same dish. Oligodendrocyte precursors were expanded
with platelet-derived growth factor- and fibroblast growth
factor-supplemented SATO medium for 2 days and sub-
sequently differentiated with 1% horse serum-supple-
mented SATO medium for 3 days.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde in PBS for 15
minutes at room temperature. The cultures were perme-
abilized and blocked in PBS supplemented with 0.1%
Triton X-100 and 10% fetal calf serum. Cells were then
incubated with antibodies against neuronal-specific nu-
clear protein (NeuN, 1:50), glial fibrillary acidic protein
(GFAP, 1:100; DAKO, Glostrup, Denmark), and myelin-
associated glycoprotein (MAG; 1:100; Chemicon, Te-
mecula, CA) diluted in 1% BSA in PBS at 4°C overnight.
After washing, cells were incubated with goat anti-mouse
secondary antibodies conjugated with Alexa 546 (1: 200;
Molecular Probes, Eugene, OR) or with donkey anti-rab-
bit secondary antibodies conjugated with fluorescein iso-
thiocyanate (1:50; Jackson Laboratory, Bar Harbor, ME).
Nuclear staining was performed with DAPI.
Results
We generated a recombinant lentiviral vector transducing
PrP-Fc2 (henceforth termed PrPFc; Figure 1a). In a first
series of experiments we investigated whether PrPFc,
when precisely targeted to a defined group of cells,
would afford local protection. We therefore injected a
relatively small amount of PrPFc (3  108 infectious
units in 5 l) into a group of five mice intrahippocampally
under stereotaxic guidance. Controls were injected with
PBS (n  5). One mouse from each group was sacrificed
6 months after virus injection to provide a first indication
about disease progression. PrP-Fc2 was detected by
immunohistochemistry in the injected hippocampus, but
not in the contralateral hemisphere (Figure 1b, top row).
Accordingly, lentiviral integration in the brain was dem-
onstrated by PCR analysis (Figure 1c). No adverse reac-
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tions were detected by conventional histology (Figure
1d), nor by immunohistochemistry with various astroglial,
microglial, and inflammatory markers (GFAP, CD11b,
Iba-1; data not shown).
Twenty days after virus injection, four PrPFc-treated
mice and four PBS controls were inoculated intracere-
brally with 3  102 LD50 RML prions. All PBS-injected
control animals succumbed to disease [177  8 days
postintracerebral prion inoculation (dpi)], whereas none
of the PrPFc-treated animals showed clinical signs at
177 dpi (Figure 1f). One clinically unaffected PrPFc-
treated mouse was sacrificed at 170 dpi and analyzed for
the presence of PrPSc by histoblotting. Whereas PBS-
treated animals showed massive PrPSc accumulation, the
PrPFc-injected mouse showed markedly reduced accu-
mulation of PrPSc in the injected hippocampus. Impor-
tantly, ipsilateral reduction in PrPSc signal intensity ex-
tended well beyond the track of the stereotaxic needle,
suggesting that PrPFc exerts long-range antiprion ef-
fects. In the contralateral hemisphere, however, PrPSc
Figure 1. Intrahippocampal lentiviral transfer of PrP-Fc2. a: Schematic representation of the transfer vector used in this study. b: Hippocampal PrP-Fc2 expression
in the injected hippocampus (top row) coincided with suppressed prion pathogenesis in PrPFc-treated mice sacrificed at 170 dpi (middle and bottom rows),
as assessed by immunohistochemistry using an anti-human Fc antibody. c: PCR using primers indicated in a of various tissues and genotypes showing
brain-specific lentiviral integration. Genomic actin amplification served for normalization of the PrPFc signal (concentration of genomic DNA in crude extract from
the tissue samples was not controlled in this experiment). d: No pathology in the brain was associated with the lentiviral injection as determined by H&E staining
and by various markers (GFAP, CD11b, Iba-1; data not shown) in nonprion inoculated mice. e: Histoblots showed a broad area of decreased PrPSc deposition
extending well beyond the site of PrPFc injection (arrow). In contrast, PrPSc signals were saturated in the contralateral hemisphere and in a PBS-treated brain.
f: Survival plots displaying the incubation time until development of terminal scrapie in PBS- and PrPFc-treated mice after intracerebral challenge. Median disease
onset was delayed by 36 days in intrahippocampally PrPFc-treated mice. LTR, long terminal repeats; CMV, cytomegalovirus; SD, splice donor; SA, splice acceptor;
	, packaging sequence; GA, 5 portion of gag gene with truncated reading frame including extended packaging signal; RRE, rev response element (RRE); cPPT,
central polypurine tract; WPRE, posttranscriptional regulatory element from the genome of the woodchuck hepatitis virus.
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deposition was indistinguishable from that of PBS-treated
controls (Figure 1e). Histological analysis failed to reveal
any vacuolation and astrogliosis in the ipsilateral hip-
pocampus (Figure 1b, middle and bottom rows). The
contralateral side presented with rather strong vacuola-
tion and astrogliosis, although the corresponding region
of a terminally sick PBS-treated animal may have been
more strongly affected (Figure 1b, middle and bottom
rows). PrPFc-injected mice succumbed to disease at
213  6 dpi (Figure 1f), which is remarkable, considering
substantial vacuolation and PrPSc deposits detected in
the contralateral side of the PrPFc-injected mice sacri-
ficed for analysis at 170 dpi (see above; Figure 1b, mid-
dle row; and Figure 1e, bottom row). Therefore, a single
Figure 2. Intracerebral lentiviral vector administration. a: Western blot analysis of frontal brain of transgenic PrP-Fc2 mice,
8 and PBS-treated and PrPFc-treated
animals. Using anti-PrP antibody,3 sustained PrP-Fc2 expression was detected 6 months after virus injection in the brain of PrPFc-treated animals, but not in the
spleen. b: Severe spongiosis and astrogliosis in terminally sick PBS-treated animals, but no sign of prion-associated pathology in a PrPFc-treated animal sacrificed
170 dpi, similarly to age-match uninoculated mice. Sections were stained with H&E and immunostained with GFAP for detection of astrocytosis. c. Whereas PrPSc
signals were visible in wt brains and spinal cords at terminal stage, no or weak signals were present in the brain and spinal cord of a PrPFc-treated animal
sacrificed at the same time point. However, spleens of treated and controls animals exhibited similar quantities of PrPSc. d: NaPTA-enhanced quantitative Western
analysis showed that PrPSc accumulation in the tested PrPFc-treated brain was 0.03% of the tested PBS-treated brain. To reach a comparable intensity level for
Western blot quantification, control samples were diluted linearly up to 32 times, whereas for PrPFc-treated brains, PrPSc was concentrated by NaPTA
precipitation from 125- or 250-fold more starting material than was used directly for Western blot in the case of PBS-treated mouse, lane 1. e: Prion infectivity,
determined in the brain of one PrPFc-treated animal by the scrapie cell assay in endpoint format (SCEPA), was reduced by 4.2 log TCl/g tissue compared to
PBS-treated animals. f: Survival of scrapie-infected mice treated with PBS or PrPFc. Whereas PBS-treated mice (n  4) succumbed to disease at 175  5 dpi,
PrPFc-treated animals (n  3) had an extended survival of 72 days (247  8 dpi).
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unilateral hippocampal injection sufficed to delay onset of
disease by 36 days (P  0.01) as compared to PBS-
injected controls.
The above results, along with the observation that the
antiprion action of PrP-Fc2 is dose-dependent in trans-
genic mice,8,25 encouraged us to explore whether non-
stereotaxic delivery of a larger number of PrPFc parti-
cles would enhance protection. We injected 30 l of
PrPFc (1.5 109 infectious units) intracerebrally into the
right telencephalic hemisphere of mice (n  4), and
inoculated them with 3  102 LD50 RML prions intrace-
rebrally 20 days later. Six months after virus injection,
immunoblot analysis revealed sustained PrP-Fc2 expres-
sion in brains of PrPFc-treated mice (Figure 2a).
We sacrificed one presymptomatic PrPFc-treated
mouse and two terminally sick PBS-treated mice at 171
dpi to estimate prion pathogenesis at this experimental
paradigm. Profound histopathological changes were
identified in PBS-treated brains (Figure 2b). In contrast,
the PrPFc-treated brain displayed no spongiform
changes ipsi- or contralaterally. Astrogliosis, estimated
by GFAP immunoreactivity, was similar to age-matched
uninfected mice (Figure 2b).
Brain, spinal cord, and spleen homogenates were sub-
jected to proteinase K (PK) digestion and analyzed for
accumulation of PrPSc by Western blot analysis. Surpris-
ingly, whereas wild-type (wt) animals showed extensive
buildup of PrPSc, no PrPSc was detectable in the brain of
the PrPFc-treated animal and only traces thereof in the
spinal cord (Figure 2c). Conversely, spleens from all
animals showed similar accumulation of PrPSc, suggest-
ing that protection was restricted to the central nervous
system (CNS) (Figure 2c). To increase the sensitivity of
PrPSc detection, we concentrated PrPSc by differential
precipitation with sodium phosphotungstic acid (NaPTA).
Quantitative Western blot analysis4 showed that PrPSc
accumulation in PrPFc-treated brain was 0.03% of PBS-
treated brain. To reach a comparable intensity level for
Western blot quantification, control samples were diluted
linearly up to 32 times, whereas for PrPFc-treated
brains, PrPSc was concentrated by NaPTA precipitation
from 125- or 250-fold more starting material than is was
used directly for Western blot in the case of PBS-treated
mouse, lane 1 (Figure 2d). Prion infectivity titers deter-
mined by end-point scrapie cell assay21 were similar in
spleens of PBS- and PrPFc-treated mice [4.1 and 4.6
log infectious tissue culture units (TCI U)/g tissue, re-
spectively, Figure 2e]. In contrast, prion titers in control
brains (n 2) reached 7.6 log TCI U/g tissue, but only 3.4
log TCI U/g tissue in the treated animal (Figure 2e).
Typical progressive signs of scrapie, including ataxia
and kyphosis, led to terminal disease in all PBS-treated
mice by 175  5 dpi (n  4). In contrast, PrPFc-treated
animals succumbed to prion disease at 247  8 dpi (n 
3), suggesting remarkable resistance to the disease (72
days) and extending their lifespan by more than 40%
(Figure 2f). Therefore, single-dose gene transfer of PrPFc
provides very potent protection against prion disease,
and suppresses prion replication by 
10,000-fold.
Next, we tested whether PrP-Fc2 might afford postex-
posure prophylaxis. Mice were inoculated with 3  102
LD50 RML prions intracerebrally and, 30 days later, intra-
cerebrally treated with PrPFc (1.5  109 IU; n  7).
Control animals injected with GFPFc (0.8  109 IU; n 
6) succumbed to scrapie at 163  4 dpi, whereas
PrPFc-treated animals survived 188  11 days (P 
0.01) (Figure 3a). Terminally sick mice from both groups
showed similar PrPSc accumulation in their brains (data
not shown). We then administered PrPFc at 121 dpi,
when scrapie-induced brain damage is already evident
by histology (A.A., unpublished data). GFPFc (n  7)-
and PrPFc (n  8)-treated animals succumbed with
similar incubation times (197  17 dpi and 197  9 dpi,
respectively), suggesting that treatment at this stage is
ineffective (Figure 3b). Importantly, we detected by
ELISA anti-GFP antibodies in serum of the GFPFc-
treated mice and anti-human Fc antibodies in serum of
the GFPFc-treated mice and PrPFc-treated mice (data
not shown). This indicates that secreted GFP-Fc2 and
PrP-Fc2, both fused to human Fc, crossed the blood-
brain-barrier, and were processed by the murine immune
system as immunogens. Induction of the transgene-spe-
cific antibodies may affect prion propagation. It has been
reported that chronic activation of the immune system in
the periphery facilitates prion pathogenesis.26–28 This
may also explain faster onset of disease seen for the
groups treated with the same lentivirus at 30 dpi com-
pared to 121 dpi. (Figure 3, a and b).
Figure 3. Intracerebral lentiviral vector transfer during prion disease pro-
gression. a: Survival plots displaying the incubation time until development
of terminal scrapie in GFPFc and PrPFc (n  7) mice treated 30 days after
RML prion inoculation. Median disease onset was delayed by 25 days in
PrPFc-treated mice. b: When prion-inoculated mice were injected with
PrPFc 121 dpi, they succumbed at the same time as GFPFc-treated mice
(respectively, 197  17 dpi and 197  9 dpi).
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We then sought to determine whether peripherally ex-
pressed PrP-Fc2 contributes to the antiprion effect. We used
transplantation of genetically modified BM progenitors, be-
cause this techniquemay represent a gene therapy vehicle.
BM of PrP-Fc2-expressing mice (tg588
CMV)8 or of wt mice
was transferred to wt or to tg588CMV mice. Eight weeks after
BM grafting, the concentration of PrP-Fc2 was assessed in
peripheral blood by ELISA (Figure 4a). Blood PrP-Fc2 con-
centrations of tg588CMV mice that had received wt BM
approached those of tg588CMV3tg588CMV mice and were
four to six times higher than those of wt mice reconstituted
with tg588CMV BM, indicating that circulating PrP-Fc2 is
mainly contributed by nonhematopoietic radioresistant cells
(Figure 4a).
Twelve weeks after reconstitution, chimeric mice were
challenged intraperitoneally with 103 LD50 RML prions. At
50 dpi, immunoblot analysis showed that PrPSc accumu-
lation was reduced in spleens of tg588CMV3wt (n  2)
and wt3tg588CMV (n  2) compared to wt3wt mice
(Figure 4b). Accordingly, splenic prion titers in
tg588CMV3wt (n 2) were 1.2 log lower than wt3wt (n
2) (Figure 4c) and wt3tg588 spleen (n  1) showed no
detectable infectivity (Figure 4c). Wt3wt mice (n  3)
and tg588CMV3wt mice (n  3) developed scrapie with
identical latency (232  7 dpi and 232  6 dpi, respec-
tively), whereas wt3tg588CMV (n  4) and
tg588CMV3tg588CMV (n  2) were affected later (300 
21 dpi and 337 25 dpi, respectively) (Figure 4d). These
results indicate that PrP-Fc2-expressing hematopoietic
cells antagonized PrPSc accumulation and prion replica-
tion, yet failed to modify the clinical course of prion
disease.
Replication-defective lentiviral vectors are not ex-
pected to spread throughout the brain after a single
unilocular injection.29 PrP-Fc2 may therefore owe its po-
tent antiprion efficacy to secretion and extracellular
spread. This scenario assumes that PrP-Fc2 would be
capable of antagonizing PrPSc deposition and prion rep-
lication in a noncell autonomous manner. We tested this
hypothesis in tg550Stop mice, which bear a PrP-Fc2
transgene preceded by a loxP-flanked transcriptional
stop cassette.8 tg550Stop mice8 were bred to nestin/
Cre10 (tg550Nestin), GFAP/Cre11 (tg550GFAP), or PLP/Cre-
ERT212 (tg550PLP) recombinator mice, activating expres-
sion of PrP-Fc2 in the entire CNS, in astrocytes, or in
oligodendrocytes, respectively. Before prion inoculation,
tg550Stop  PLP/Cre-ERT2, tg550Stop (but Cre-nega-
tive), and PLP/Cre-ERT2 (but tg550Stop-negative) litter-
mates were treated daily with 2 mg of tamoxifen intraperi-
toneally for 5 days to activate Cre recombination.12
Figure 4. Effects of hematopoietically expressed PrP-Fc2. a: PrP-Fc2 titers (relative units) in blood of chimeric mice. tg5883wt reconstituted mice showed weaker
PrP-Fc2 expression than tg588 mice. b: Fifty days after RML prion inoculation, spleens from tg5883wt and wt3 tg588 showed decreased accumulation of PrP
Sc
compared to wt3wt spleens. c: Infectivity titer of wt3 tg588 (n  1) was below detectability and those of tg5883wt (n  2) were 1.2 log lower than wt3wt
(n  2, average is represented) controls. d: wt3wt and tg5883wt reconstituted mice succumbed to scrapie at the same stage, whereas wt3 tg588 and tg5883
tg588 mice were retarded.
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Restriction of transgene expression to the specified
cell populations was tested on primary cell cultures of
cerebellar granule neurons, astrocytes, and oligodendro-
cytes from tg550Nestin, tg550GFAP, and tg550PLP mice.
Purity in these primary cultures was typically 
95%, as
determined by specific cellular marker stains (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org). Cells
were lysed and subjected to Western blot analysis for
PrP-Fc2 (see Supplemental Figure S2 at http://ajp.amjpathol.
org). Expression of PrP-Fc2 was relatively weak in
tg550PLP oligodendrocytes (maybe because the Prnp
promoter is weakly active in oligodendrocytes30,31), but
undetectable in neurons and astrocytes (see Supplemen-
tal Figure S2 at http://ajp.amjpathol.org). Tg550Nestin
showed sustained generalized PrP-Fc2 expression in the
CNS, whereas PrP-Fc2 was mainly secreted by
tg550GFAP astrocytes (see Supplemental Figure S2 at
http://ajp.amjpathol.org).
Tg550Nestin, tg550GFAP, and littermate control mice
were inoculated with 3  102 LD50 RML prions intrace-
rebrally or 103 LD50 RML prions intraperitoneally. Typical
signs of scrapie, including ataxia and kyphosis, occurred
in all inoculated mice. However, tg550Nestin and
tg550GFAP mice showed delayed disease after intracere-
bral inoculation (151 and 65 days, respectively; P 0.01)
(Figure 5, a and c) and after intraperitoneal inoculation
(90 and 65 days, respectively; P  0.01) (Figure 5, b and
d). Astrocytes have been shown to be competent for
prion replication,32 although the toxicity of astrocytic
PrPSc to neurons is somewhat controversial.33,34
To determine whether PrP-Fc2 exerts its antiprion ef-
fect when produced by cells resistant to prion infection,
we inoculated tg550PLP, which expressed PrP-Fc2 selec-
tively in oligodendrocytes (see Supplemental Figure S2 at
http://ajp.amjpathol.org) and Schwann cells.12 Trans-
genic mice expressing PrP under the control of the myelin
basic protein-promoter are resistant to prion infection,
suggesting that oligodendrocytes and Schwann cells do
not support cell-autonomous prion replication and neural
spread of prions.31
We found that tg550PLP mice (n 8), which expressed
low amounts of PrP-Fc2, showed delayed disease over
tamoxifen-treated tg550Stop and PLP/Cre-ERT2 mice.
The delay was 35 days (P  0.01) after intracerebral
inoculation (Figure 5e) and 50 days (P  0.01) after
intraperitoneal inoculation (Figure 5f). Terminal illness
was unambiguously accompanied by clinical scrapie
signs. Spleens from tg550Nestin, tg550GFAP, tg550PLP, and
controls did not show any PrP-Fc2 expression (see Sup-
plemental Figure S3a at http://ajp.amjpathol.org) nor any
difference in their accumulation of PrPSc (see Supple-
mental Figure S3b at http://ajp.amjpathol.org).
Determination of prion titers19 50 days after intracere-
bral inoculation demonstrated that all spleens from
tg550Nestin, tg550GFAP, and tg550PLP and their littermate
controls contained approximately the same infectivity,
Figure 5. Protection against scrapie can be mediated both by neuronally and glially restricted expression of PrP-Fc2. a–f: Survival plots of scrapie-infected
transgenic mice expressing PrP-Fc2 in the entire CNS (a, b), in astrocytes (c, d), or in oligodendrocytes (e, f) after intracerebral (a, c, e) or intraperitoneal RML
prion inoculation (b, d, f). Expression of PrP-Fc2 in oligodendrocytes, which are inherently resistant to scrapie, delayed prion disease, suggesting a noncell
autonomous antiprion effect. g: Immunoblot analysis revealed reduced levels of PrPSc in brains of transgenic mice expressing PrP-Fc2 cells specifically. h: GFAP
staining indicated diminished pathological changes, in agreement with delayed disease progression.
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confirming the similar prion replication rate in spleens of
each genotype (see Supplemental Table S1 at http://
ajp.amjpathol.org). Although brains of wt mice contained
prion titers between 2.7 to 4.5 log LD50/g tissue after 50
dpi intracerebrally, tg550Nestin, tg550GFAP, and tg550PLP
brain titers were below detectability. At 100 dpi, tg550Nestin
brain titers were still reduced compared to wt controls (see
Supplemental Table S1 at http://ajp.amjpathol.org).
Immunoblot analysis of PrPSc in tg550Nestin, tg550GFAP,
tg550PLP, and wt littermate brains revealed similar PrPSc
deposition at terminal disease (Figure 5g). In contrast,
tg550Nestin, tg550GFAP, and tg550PLP sacrificed at the
time at which wt controls mice had developed terminal
scrapie, showed markedly reduced PrPSc accumulation
(Figure 5g). With the caveat that Western blot analyses
are only semiquantitative, this suggests that PrPSc dep-
osition is counteracted even when PrP-Fc2 is expressed
by CNS cells unable to replicate prions.
Next, we analyzed neuropathological changes during
the course of the disease. At terminal stage (181/183/224
dpi), all control animals showed pathological evidence of
neuroinvasive CNS scrapie infection to a similar extent
(Figure 5h and data not shown). At these time points,
tg550Nestin mice showed only weak astrogliosis, vacuo-
lation, and PrPSc deposition (Figure 5h and data not
shown), whereas in tg550GFAP and tg550PLP mice, neu-
ropathological changes were more advanced, as re-
flected by astrocytosis, PrPSc deposition, and spongiform
degeneration (Figure 5h and data not shown), but were
still reduced in comparison to wt sick mice. Therefore,
PrP-Fc2 not only delays PrP
Sc accumulation in the brain,
but also retards histopathological changes. The entirety
of the above results strongly suggests that PrP-Fc2 de-
lays PrPSc accumulation and prion disease in a noncell
autonomous manner.
Discussion
We have explored in vivo gene therapy in a mouse model of
prion disease. Our approach resulted in sustained expres-
sion of a soluble prion antagonist in the brain, impaired
replication of disease-associated PrPSc, effective neuro-
pathological protection, and delayed disease progression.
Even though lentiviral transduction is limited to the site of
injection,29 PrPSc accumulation was decreased in most of
the brain. The most plausible interpretation is that secreted
PrP-Fc2 was released into the cerebrospinal fluid, where it
antagonized PrPSc replication noncell autonomously, as
suggested in a previous report.8
Why was PrPFc less efficient to delay prion pathogen-
esis when delivered during disease progression? Trans-
gene expression may take 4 to 6 weeks before reaching its
maximum.35 Therefore, after injection at 30 dpi, high ex-
pression of PrP-Fc2 was achieved in the brain 60 to 75
dpi, when prion infectivity and PrPSc have already colonized
the brain. Indeed, we detected PrPSc in the brain by West-
ern blot as early as 58 dpi (data not shown). Because there
is a competitive interaction between PrP-Fc2 and PrP
C for
PrPSc,8 the presence of substoichiometric PrP-Fc2 may not
be sufficient to efficiently prevent PrPSc formation and may
only weakly slow down its accumulation.
Direct gene delivery of a soluble prion antagonist into
the CNS by lentiviral vectors may be an effective strategy
against prion diseases. In contrast, almost all previous
therapeutic interventions only showed benefits after ex-
tracerebral injection, probably reflecting the difficulty of
most of the drugs to cross the blood-brain barrier.3,36–38
Because variant Creutzfeld-Jakob disease can be diag-
nosed before death on lymphoid tissues39 and patients
may display extraneural PrPSc long before neuroinva-
sion,40 gene delivery of prion antagonists directly in the
brain may be sufficient to block PrPSc before it has al-
ready colonized the CNS. In this context, our findings
may provide a promising new approach to prion
therapeutics.
Acknowledgments
We thank D. Robay and G. Bosshard for technical help,
Harald Seeger for determination of prion titers by scrapie-
cell assay, S. Marino for GFAP/Cre mice, M. Kawe and A.
Plu¨ckthun for purified GFP-His, A. Audige´ for p24 ELISA,
M. Glatzel and F. Heppner for mouse inoculation, C.
Weissmann for critical reading of the manuscript, and the
Lentiviral Vector Production Unit of the Swiss Institute of
Technology Lausanne (EPFL, supported by the Associa-
tion Franc¸aise contre les Myopathies) for providing lenti-
virus production.
References
1. Aguzzi A, Sigurdson CJ: Antiprion immunotherapy: to suppress or to
stimulate? Nat Rev Immunol 2004, 4:725–736
2. Aguzzi A, Glatzel M, Montrasio F, Prinz M, Heppner FL: Interventional
strategies against prion diseases. Nat Rev Neurosci 2001, 2:745–749
3. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S,
Anstee D, Collinge J, Hawke S: Monoclonal antibodies inhibit prion
replication and delay the development of prion disease. Nature 2003,
422:80–83
4. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B,
Zinkernagel RM, Kalinke U, Aguzzi A: Prevention of scrapie patho-
genesis by transgenic expression of anti-prion protein antibodies.
Science 2001, 294:178–182
5. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M,
Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E,
Gilden D, Oldstone MB, Conti B, Williamson RA: Cross-linking cellular
prion protein triggers neuronal apoptosis in vivo. Science 2004,
303:1514–1516
6. Schwarz A, Kratke O, Burwinkel M, Riemer C, Schultz J, Henklein P,
Bamme T, Baier M: Immunisation with a synthetic prion protein-
derived peptide prolongs survival times of mice orally exposed to the
scrapie agent. Neurosci Lett 2003, 350:187–189
7. Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N,
Wopfner F, Schaetzl H, Becher B, Aguzzi A: Humoral immune re-
sponse to native eukaryotic prion protein correlates with anti-prion
protection. Proc Natl Acad Sci USA 2004, 101:14670–14676
8. Meier P, Genoud N, Prinz M, Maissen M, Rulicke T, Zurbriggen A,
Raeber AJ, Aguzzi A: Soluble dimeric prion protein binds PrP(Sc) in
vivo and antagonizes prion disease. Cell 2003, 113:49–60
9. Follenzi A, Naldini L: Generation of HIV-1 derived lentiviral vector.
Methods Enzymol 2002, 346:454–465
10. Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock
R, Klein R, Schutz G: Disruption of the glucocorticoid receptor gene
Antiprion Prophylaxis by PrP-Fc2 1295
AJP May 2008, Vol. 172, No. 5
in the nervous system results in reduced anxiety. Nat Genet 1999,
23:99–103
11. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A: Induction
of medulloblastomas in p53-null mutant mice by somatic inactivation
of Rb in the external granular layer cells of the cerebellum. Genes Dev
2000, 14:994–1004
12. Leone DP, Genoud S, Atanasoski S, Grausenburger R, Berger P,
Metzger D, Macklin WB, Chambon P, Suter U: Tamoxifen-inducible
glia-specific Cre mice for somatic mutagenesis in oligodendrocytes
and Schwann cells. Mol Cell Neurosci 2003, 22:430–440
13. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenu-
ated lentiviral vector achieves efficient gene delivery in vivo. Nat
Biotechnol 1997, 15:871–875
14. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A:
Coexistence of multiple PrPSc types in individuals with Creutzfeldt-
Jakob disease. Lancet Neurol 2005, 4:805–814
15. Kawe M, Plu¨ckthun A: GroEL walks the fine line: the subtle balance of
substrate and co-chaperonin binding by GroEL. A combinatorial in-
vestigation by design, selection and screening. J Mol Biol 2006,
357:411–426
16. Genoud N, Behrens A, Miele G, Robay D, Heppner FL, Freigang S,
Aguzzi A: Disruption of Doppel prevents neurodegeneration in mice
with extensive Prnp deletions. Proc Natl Acad Sci USA 2004,
101:4198–4203
17. Brandner S, Raeber A, Sailer A, Blattler T, Fischer M, Weissmann C,
Aguzzi A: Normal host prion protein (PrPC) is required for scrapie
spread within the central nervous system. Proc Natl Acad Sci USA
1996, 93:13148–13151
18. Bu¨eler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann C:
High prion and PrPSc levels but delayed onset of disease in scrapie-
inoculated mice heterozygous for a disrupted PrP gene. Mol Med
1994, 1:19–30
19. Fischer M, Ru¨licke T, Raeber A, Sailer A, Moser M, Oesch B, Brand-
ner S, Aguzzi A, Weissmann C: Prion protein (PrP) with amino-prox-
imal deletions restoring susceptibility of PrP knockout mice to
scrapie. EMBO J 1996, 15:1255–1264
20. Kaeser PS, Klein MA, Schwarz P, Aguzzi A: Efficient lymphoreticular
prion propagation requires prp(c) in stromal and hematopoietic cells.
J Virol 2001, 75:7097–7106
21. Klo¨hn PC, Stoltze L, Flechsig E, Enari M, Weissmann C: A quantita-
tive, highly sensitive cell-based infectivity assay for mouse scrapie
prions. Proc Natl Acad Sci USA 2003, 100:11666–11671
22. Schulz JB, Weller M, Klockgether T: Potassium deprivation-induced
apoptosis of cerebellar granule neurons: a sequential requirement for
new mRNA and protein synthesis. ICE-like protease activity, and
reactive oxygen species. J Neurosci 1996, 16:4696–4706
23. Trotter J, Schachner M: Cells positive for the O4 surface antigen
isolated by cell sorting are able to differentiate into astrocytes or
oligodendrocytes. Brain Res Dev Brain Res 1989, 46:115–122
24. McCarthy KD, de Vellis J: Preparation of separate astroglial and
oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol
1980, 85:890–902
25. Masel J, Genoud N, Aguzzi A: Efficient inhibition of prion replication
by PrP-Fc(2) suggests that the prion is a PrP(Sc) oligomer. J Mol Biol
2005, 345:1243–1251
26. Aguzzi A, Heikenwalder M: Pathogenesis of prion diseases: current
status and future outlook. Nat Rev Microbiol 2006, 4:765–775
27. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel
RM, Carroll MC, Verbeek JS, Botto M, Walport MJ, Molina H, Kalinke
U, Acha-Orbea H, Aguzzi A: Complement facilitates early prion
pathogenesis. Nat Med 2001, 7:488–492
28. Combrinck MI, Perry VH, Cunningham C: Peripheral infection evokes
exaggerated sickness behaviour in pre-clinical murine prion disease.
Neuroscience 2002, 112:7–11
29. Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, Trojani
A, Benaglia G, Marchesini S, Cestari V, Oliverio A, Bordignon C,
Naldini L: In vivo gene therapy of metachromatic leukodystrophy by
lentiviral vectors: correction of neuropathology and protection against
learning impairments in affected mice. Nat Med 2001, 7:310–316
30. Moser M, Colello RJ, Pott U, Oesch B: Developmental expression of
the prion protein gene in glial cells. Neuron 1995, 14:509–517
31. Prinz M, Montrasio F, Furukawa H, van der Haar ME, Schwarz P,
Ru¨licke T, Giger O, Ha¨usler KG, Glatzel M, Aguzzi A: Intrinsic resis-
tance of oligodendrocytes to prion infection. J Neurosci 2004,
24:5974–5981
32. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA,
Mucke L, Manson J, Aguzzi A, Oldstone MB, Weissmann C, Chese-
bro B: Astrocyte-specific expression of hamster prion protein (PrP)
renders PrP knockout mice susceptible to hamster scrapie. EMBO J
1997, 16:6057–6065
33. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J:
Depleting neuronal PrP in prion infection prevents disease and re-
verses spongiosis. Science 2003, 302:871–874
34. Jeffrey M, Goodsir CM, Race RE, Chesebro B: Scrapie-specific neu-
ronal lesions are independent of neuronal PrP expression. Ann Neurol
2004, 55:781–792
35. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L: Gene transfer by
lentiviral vectors is limited by nuclear translocation and rescued by
HIV-1 pol sequences. Nat Genet 2000, 25:217–222
36. Cashman NR, Caughey B: Prion diseases—close to effective ther-
apy? Nat Rev Drug Discov 2004, 3:874–884
37. Montrasio F, Frigg R, Glatzel M, Klein MA, Mackay F, Aguzzi A,
Weissmann C: Impaired prion replication in spleens of mice lacking
functional follicular dendritic cells. Science 2000, 288:1257–1259
38. Mabbott NA, McGovern G, Jeffrey M, Bruce ME: Temporary blockade
of the tumor necrosis factor receptor signaling pathway impedes the
spread of scrapie to the brain. J Virol 2002, 76:5131–5139
39. Hill AF, Zeidler M, Ironside J, Collinge J: Diagnosis of new variant
Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997, 349:99–100
40. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J: Prion immu-
noreactivity in appendix before clinical onset of variant Creutzfeldt-
Jakob disease. Lancet 1998, 352:703–704
1296 Genoud et al
AJP May 2008, Vol. 172, No. 5
